Equities Analysts Issue Forecasts for ASMB Q1 Earnings

Assembly Biosciences, Inc. (NASDAQ:ASMB) – Investment analysts at HC Wainwright issued their Q1 2027 earnings estimates for Assembly Biosciences in a report issued on Thursday, March 26th. HC Wainwright analyst P. Trucchio expects that the biopharmaceutical company will earn ($0.16) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $50.00 price target on the stock. The consensus estimate for Assembly Biosciences’ current full-year earnings is ($6.87) per share. HC Wainwright also issued estimates for Assembly Biosciences’ Q2 2027 earnings at ($1.13) EPS, Q3 2027 earnings at ($1.10) EPS, Q4 2027 earnings at $1.67 EPS and FY2030 earnings at $3.23 EPS.

Assembly Biosciences (NASDAQ:ASMB) last issued its quarterly earnings results on Thursday, March 19th. The biopharmaceutical company reported $2.48 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.51) by $2.99. Assembly Biosciences had a negative net margin of 8.47% and a negative return on equity of 5.63%. The company had revenue of $42.47 million during the quarter, compared to the consensus estimate of $7.42 million.

A number of other brokerages also recently commented on ASMB. Wall Street Zen upgraded shares of Assembly Biosciences from a “hold” rating to a “buy” rating in a research note on Saturday, March 21st. Weiss Ratings restated a “sell (d-)” rating on shares of Assembly Biosciences in a research note on Wednesday, January 21st. Five analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $41.75.

Assembly Biosciences Trading Down 4.1%

Shares of NASDAQ:ASMB opened at $27.70 on Friday. Assembly Biosciences has a 52 week low of $7.75 and a 52 week high of $39.71. The company’s 50 day moving average is $27.93 and its two-hundred day moving average is $29.74. The company has a market cap of $439.32 million, a PE ratio of -37.43 and a beta of 1.11.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the company. Informed Momentum Co LLC increased its position in Assembly Biosciences by 1.6% during the fourth quarter. Informed Momentum Co LLC now owns 29,523 shares of the biopharmaceutical company’s stock worth $1,004,000 after buying an additional 451 shares during the period. ADAR1 Capital Management LLC boosted its holdings in shares of Assembly Biosciences by 4.2% in the fourth quarter. ADAR1 Capital Management LLC now owns 19,747 shares of the biopharmaceutical company’s stock valued at $672,000 after acquiring an additional 800 shares during the period. Geode Capital Management LLC grew its position in shares of Assembly Biosciences by 0.9% during the fourth quarter. Geode Capital Management LLC now owns 131,307 shares of the biopharmaceutical company’s stock worth $4,468,000 after acquiring an additional 1,212 shares during the last quarter. Palumbo Wealth Management LLC grew its position in shares of Assembly Biosciences by 7.2% during the fourth quarter. Palumbo Wealth Management LLC now owns 37,305 shares of the biopharmaceutical company’s stock worth $1,269,000 after acquiring an additional 2,507 shares during the last quarter. Finally, Bank of America Corp DE increased its holdings in shares of Assembly Biosciences by 6,382.7% in the 3rd quarter. Bank of America Corp DE now owns 3,371 shares of the biopharmaceutical company’s stock valued at $86,000 after acquiring an additional 3,319 shares during the period. Hedge funds and other institutional investors own 19.92% of the company’s stock.

About Assembly Biosciences

Assembly Biosciences, Inc (NASDAQ: ASMB) is a clinical-stage biotechnology company dedicated to the discovery, development and commercialization of novel therapies for hepatitis B virus (HBV) and hepatitis D virus (HDV) infections. The company’s core expertise lies in small-molecule modulation of viral proteins and host-targeted pathways to achieve sustained viral suppression and potential functional cure. Assembly’s research model integrates medicinal chemistry, structural biology and translational virology to advance its pipeline from early discovery through clinical development.

The company’s lead programs include core protein allosteric modulators (CpAMs) designed to disrupt the HBV lifecycle by interfering with capsid assembly and viral DNA replication, as well as prenylation inhibitors targeting the HDV lifecycle.